Literature DB >> 7683428

Characterization of a high-affinity galanin receptor in the rat anterior pituitary: absence of biological effect and reduced membrane binding of the antagonist M15 differentiate it from the brain/gut receptor.

D Wynick1, D M Smith, M Ghatei, K Akinsanya, R Bhogal, P Purkiss, P Byfield, N Yanaihara, S R Bloom.   

Abstract

Structure-activity studies demonstrate that galanin fragments 1-15 and 2-29 are fully active, whereas fragment 3-29 has been reported to be inactive, in a number of different in vivo models. M15, a chimeric peptide comprising galanin 1-13 and substance P5-11, has recently been found to be a potent galanin antagonist. Direct effects of galanin at the level of the pituitary have been defined, yet, paradoxically, a number of studies have been unable to demonstrate galanin binding to an anterior pituitary receptor. Porcine galanin stimulated prolactin release from dispersed rat anterior pituitary cells up to 180% +/- 12% (mean +/- SEM) of control secretion. The addition of a specific galanin antiserum caused a profound inhibition of basal prolactin release, maximal inhibition being 12% +/- 0.5% of control secretion. Addition of M15 produced no effect on basal or galanin-stimulated prolactin release. Galanin fragment 3-29 was fully active when compared to galanin 1-29. Fragments 5-29 and 8-29 stimulated prolactin release to a lesser extent and galanin 1-15, 10-29, and 20-29 had no significant prolactin-releasing activity. Using [mono(125I)iodo-Tyr26]galanin or porcine 125I-labeled Bolton-Hunter [mono(125I)iodo-Lys25]galanin, no anterior pituitary membrane binding was observed. In contrast, 125I-labeled Bolton-Hunter N-terminally labeled galanin allowed characterization of a single high-affinity anterior pituitary galanin receptor with a Kd of 4.4 +/- 0.34 nM and a Bmax of 79 +/- 8.3 fmol/mg of protein. The IC50 for porcine galanin was 0.51 +/- 0.04 nM but for M15 was in excess of 10 microM. Galanin 3-29 fully displaced the label with an IC50 of 0.96 +/- 0.7 nM. The IC50 for galanin 5-29 was 200 nM, whereas 8-29 and 1-15 were > 1 microM. Galanin 10-29 and 20-29 failed to displace the label. These data suggest the presence of a high-affinity pituitary galanin receptor, designated GAL-R2, in which region 3-10 and amino acid 25 are crucial for membrane binding and biological activity, in contrast to the known gut/brain galanin receptor (designated GAL-R1). A number of tissues known to bind or respond to galanin were screened. GAL-R2 would appear to be expressed only in the anterior pituitary and hypothalamus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683428      PMCID: PMC46480          DOI: 10.1073/pnas.90.9.4231

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Immunohistochemical mapping of galanin-like neurons in the rat central nervous system.

Authors:  G Skofitsch; D M Jacobowitz
Journal:  Peptides       Date:  1985 May-Jun       Impact factor: 3.750

2.  Identification and molecular characterization of galanin receptor sites in rat brain.

Authors:  A L Servin; B Amiranoff; C Rouyer-Fessard; K Tatemoto; M Laburthe
Journal:  Biochem Biophys Res Commun       Date:  1987-04-14       Impact factor: 3.575

3.  Galanin-induced inhibition of insulin secretion from rat islets: effects of rat and pig galanin and galanin fragments and analogues.

Authors:  S Gregersen; K Hermansen; U Langel; G Fisone; T Bartfai; B Ahrén
Journal:  Eur J Pharmacol       Date:  1991-10-02       Impact factor: 4.432

4.  Growth hormone (GH) release in response to GH-releasing hormone in man is 3-fold enhanced by galanin.

Authors:  T M Davis; J M Burrin; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  1987-12       Impact factor: 5.958

5.  Galanin: evidence for a hypothalamic site of action to release growth hormone.

Authors:  A Ottlecz; W K Samson; S M McCann
Journal:  Peptides       Date:  1986 Jan-Feb       Impact factor: 3.750

6.  Effects of neuropeptide Y, NPY analog (norleucine4-NPY), galanin and neuropeptide K on LH release in ovariectomized (ovx) and ovx estrogen, progesterone-treated rats.

Authors:  A Sahu; W R Crowley; K Tatemoto; A Balasubramaniam; S P Kalra
Journal:  Peptides       Date:  1987 Sep-Oct       Impact factor: 3.750

7.  Galanin - a novel biologically active peptide from porcine intestine.

Authors:  K Tatemoto; A Rökaeus; H Jörnvall; T J McDonald; V Mutt
Journal:  FEBS Lett       Date:  1983-11-28       Impact factor: 4.124

8.  Distribution of galanin immunoreactivity in the central nervous system and the responses of galanin-containing neuronal pathways to injury.

Authors:  J L Ch'ng; N D Christofides; P Anand; S J Gibson; Y S Allen; H C Su; K Tatemoto; J F Morrison; J M Polak; S R Bloom
Journal:  Neuroscience       Date:  1985-10       Impact factor: 3.590

9.  Galanin stimulates the release of vasoactive intestinal polypeptide from perifused hypothalamic fragments in vitro and from periventricular structures into the cerebrospinal fluid in vivo in the rat.

Authors:  T Inoue; Y Kato; H Koshiyama; N Yanaihara; H Imura
Journal:  Neurosci Lett       Date:  1988-02-15       Impact factor: 3.046

10.  Central galanin stimulates pituitary prolactin secretion in rats: possible involvement of hypothalamic vasoactive intestinal polypeptide.

Authors:  H Koshiyama; Y Kato; T Inoue; Y Murakami; Y Ishikawa; N Yanaihara; H Imura
Journal:  Neurosci Lett       Date:  1987-03-20       Impact factor: 3.046

View more
  19 in total

1.  Molecular cloning of a functional human galanin receptor.

Authors:  E Habert-Ortoli; B Amiranoff; I Loquet; M Laburthe; J F Mayaux
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

2.  Galanin receptor-mediated inhibition of glutamate release in the arcuate nucleus of the hypothalamus.

Authors:  G A Kinney; P J Emmerson; R J Miller
Journal:  J Neurosci       Date:  1998-05-15       Impact factor: 6.167

3.  Possible evidence for endogenous production of a novel galanin-like peptide.

Authors:  Z L Wang; R N Kulkarni; R M Wang; D M Smith; M A Ghatei; P G Byfield; W M Bennet; S R Bloom
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Expression of galanin and a galanin receptor in several sensory systems and bone anlage of rat embryos.

Authors:  Z Q Xu; T J Shi; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

6.  Galanin inhibits continuous and phasic firing in rat hypothalamic magnocellular neurosecretory cells.

Authors:  S Papas; C W Bourque
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

Review 7.  Galanin--a neuropeptide with inhibitory actions.

Authors:  K Kask; U Langel; T Bartfai
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

8.  Galanin positively modulates prolactin secretion in normal women.

Authors:  S Grottoli; E Arvat; L Gianotti; J Ramunni; L Di Vito; B Maccagno; E Ciccarelli; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

9.  New high affinity peptide antagonists to the spinal galanin receptor.

Authors:  X J Xu; Z Wiesenfeld-Hallin; U Langel; K Bedecs; T Bartfai
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

10.  Galanin-receptor ligand M40 peptide distinguishes between putative galanin-receptor subtypes.

Authors:  T Bartfai; U Langel; K Bedecs; S Andell; T Land; S Gregersen; B Ahrén; P Girotti; S Consolo; R Corwin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.